Crinetics Entered into an Exclusive License Agreement with Sanwa Kagaku Kenkyusho to Develop and Commercialize Paltusotine in Japan
Shots:
- Crinetics to receive $13.0M up front & is eligible to receive an $25.5M as an additional fee upon achievement of development, regulatory & commercial milestones along with royalties. Sanwa will be responsible for all costs associated with clinical trials & regulatory applications
- Sanwa gets an exclusive right to develop & commercialize Paltusotine in Japan and will lead the development & commercialization of the product for acromegaly & NETs in Japan. Crinetics holds all rights to develop & commercialize paltusotine outside Japan
- Paltusotine is being studied in the P-III (PATHFNDR) program for acromegaly in the US & EU. Sanwa is planning to initiate the P-I study of paltusotine in 2022 in Japan
Ref: Globe Newswire | Image: Crinetics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
